# First in Human Study of TORL-1-23 in Participants With Advanced Cancer

> **NCT05103683** · PHASE1 · RECRUITING · sponsor: **TORL Biotherapeutics, LLC** · enrollment: 90 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Ovarian Cancer
- Endometrial Cancer
- NSCLC

## Interventions

- **DRUG:** TORL-1-23

## Key facts

- **NCT ID:** NCT05103683
- **Lead sponsor:** TORL Biotherapeutics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-17
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-11-15
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05103683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05103683, "First in Human Study of TORL-1-23 in Participants With Advanced Cancer". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05103683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*